Title of Study: A Pilot Study to Measure the Impact of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01) on Markers of HIV Persistence in Blood in ART-treated, HIV-infected Adults

Brief Description: People with HIV who are on medications to block the virus still have hidden infected cells that can make virus and cause disease if HIV medications are stopped. To achieve a cure these hidden infected cells need to also be destroyed. This study is using a new treatment of human monoclonal antibodies (VRC-HIVAB060-00-AB or VRC01) against the HIV virus. Other monoclonal antibodies have been used to treat other diseases like cancer, infections and autoimmune disorders. This particular monoclonal antibody was discovered in a person infected with HIV who was able to keep their virus under control without HIV medications.

The study consists of 2 groups of study participants. The first group will receive the medication VRC01 through an intravenous line or IV at week 0 and week 4 and a placebo (normal saline) at week 12 and 16. The other group of study participants will receive placebo at week 0 and 4 and VRC01 at weeks 12 and 16. The study staff and the participant will not know which treatment participants are on.

Purpose of the Study: The goal of the study is to see if VRC01 is safe and well tolerated in individuals with HIV and also to see if it helps to remove HIV infected cells from the body. A new test will be used to measure the amount of HIV in the T-cells.

Requirements to Enter Study:
- HIV infected persons between 18 and 60 years of age.
- On HIV treatment for at least 2 years and no changes in the drug regimen for the past 90 days
- CD4 count greater than 200
- Undetectable HIV viral load for the past 2 years
- No chronic Hep B or Hep C

Treatment: VRC01 will be administered in a saline IV infusion dosed at 40mg/kg of weight. It will be administered over 60 minutes or longer. Patients must continue to take their prescribed HIV medications.

Duration of Study: Participants will be followed for 30 weeks.

For More Information Contact:

Beverly at 615-936-8516 or Beverly.o.woodward@vanderbilt.edu